Corporate Feature     

Published: May 31, 2024
Updated: May 31, 2024

Sigachi Industries Ltd

Robust earnings show for Q4FY24: Net Profit jumps 108% YoY

Sigachi Industries Limited., a leading pharmaceutical company engaged in active pharmaceutical ingredients, quality excipients, vitamin mineral nutrient blends, and O&M services, in its board meeting held on 27 May 2024 announced its audited financial results for the quarter and year ended 31 March, 2024. The board also recommended a dividend of Re.0.10 per share, subject to approval of members.

For the year ended 31 March 2024, the company saw a 32.08% growth in its revenue from operations, growing from Rs. 3020 Mn (FY23) to Rs. 3989 Mn (FY24). EBITDA grew 30.49% YoY, from Rs. 587 Mn (FY23), to Rs. 766 Mn (FY24). EBITDA margin stood at 19.20%. PAT recorded a robust growth of 31.19% YoY, from Rs. 436 Mn (FY23), to Rs. 572 Mn (FY24).

Sigachi Industries Limited, publicly listed company on NSE & BSE, is a globally recognized pharmaceutica company known for its unwavering commitment of delivering active pharmaceutical Ingredients, high-quality excipients, vitamin mineral nutrient blends, and O&M services. With over 33 years of industry experience, Sigachi has emerged as a trusted partner for pharmaceutical and nutraceutical companies spread across 62 countries. The company’s diverse product portfolio is manufactured in 5 multilocational facilities present in Telangana, Gujarat and Karnataka which are certified with global standard certifications like WHO GMP, EXCiPACT GMP, ISO, KOSHER, HALAL & many others. Being headquartered in Hyderabad, Sigachi Industries Limited has subsidiaries in US and Middle East.